Yayın:
Cystic fibrosis in Turkey: First data from the national registry

dc.contributor.buuauthorSapan, Nihat
dc.contributor.buuauthorÇekiç, Şükrü
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentDahili Tıp Bilimleri
dc.contributor.departmentÇocuk Sağlığı ve Hastalıkları Bölümü
dc.contributor.orcid0000-0002-9574-1842
dc.contributor.researcheridL-1933-2017
dc.contributor.scopusid6602156485
dc.contributor.scopusid56117061000
dc.date.accessioned2023-03-23T08:10:38Z
dc.date.available2023-03-23T08:10:38Z
dc.date.issued2019-11-11
dc.descriptionÇalışmada 41 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır.
dc.descriptionBu çalışma, 5-8 Haziran 2019 tarihlerinde Liverpool[Birleşik Krallık]'da düzenlenen 42nd European Cystic Fibrosis Conference'de bildiri olarak sunulmuştur.
dc.description.abstractBackground Cystic fibrosis (CF) care has been implemented in Turkey for a long time; however, there had been no patient registry. For this purpose, the Turkish National CF Registry was established. We present the first results of registry using data collected in 2017. Methods The data were collected using a data-entry software system, which was accessed from the internet. Demographic and annually recorded data consisted of 15 and 79 variables, respectively. Results There were 1170 patients registered from 23 centers; the estimated coverage rate was 30%. The median age at diagnosis was 1.7 years (median current age: 7.3 years); 51 (4.6%) patients were aged over 18 years. Among 293 patients who were under 3 years of age, 240 patients (81.9%) were diagnosed through newborn screening. Meconium ileus was detected in 65 (5.5%) patients. Genotyping was performed in 978 (87.4%) patients and 246 (25.2%) patients' mutations were unidentified. The most common mutation was deltaF508 with an allelic frequency of 28%, followed by N1303K (4.9%). The median FEV1% predicted was 86. Chronic colonization with Pseudomonas aeruginosa was seen in 245 patients. The most common complication was pseudo-Bartter syndrome in 120 patients. The median age of death was 13.5 years in a total of 15 patients. Conclusions Low coverage rate, lack of genotyping, unidentified mutations, and missing data of lung functions are some of our greatest challenges. Including data of all centers and reducing missing data will provide more accurate data and help to improve the CF care in Turkey in the future.
dc.identifier.citationDoğru, D. vd. (2019). ''Cystic fibrosis in Turkey: First data from the national registry''. Pediaric Pulmonology, 55(2), 541-548.
dc.identifier.doi10.1002/ppul.24561
dc.identifier.endpage548
dc.identifier.issn8755-6863
dc.identifier.issn1099-0496
dc.identifier.issue2
dc.identifier.pubmed31710166
dc.identifier.scopus2-s2.0-85075130359
dc.identifier.startpage541
dc.identifier.urihttps://doi.org/10.1002/ppul.24561
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1002/ppul.24561
dc.identifier.urihttp://hdl.handle.net/11452/31712
dc.identifier.volume55
dc.identifier.wos000495493500001
dc.indexed.scopusScopus
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherWiley
dc.relation.collaborationYurt dışı
dc.relation.collaborationSanayi
dc.relation.journalPediatric Pulmonology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectPediatrics
dc.subjectRespiratory system
dc.subjectCystic fibrosis
dc.subjectNational registry
dc.subjectPatient registry
dc.subjectPseudo-bartter-syndrome
dc.subjectCftr gene
dc.subjectTurkish
dc.subjectMutations
dc.subject.emtreeAntibiotic agent
dc.subject.emtreeAzithromycin
dc.subject.emtreeBisphosphonic acid derivative
dc.subject.emtreeBronchodilating agent
dc.subject.emtreeCalcium
dc.subject.emtreeChloride
dc.subject.emtreeColistin
dc.subject.emtreeCorticosteroid
dc.subject.emtreeDornase alfa
dc.subject.emtreeInsulin
dc.subject.emtreeMannitol
dc.subject.emtreePancreas enzyme
dc.subject.emtreeProton pump inhibitor
dc.subject.emtreeSodium chloride
dc.subject.emtreeTobramycin
dc.subject.emtreeUrsodeoxycholic acid
dc.subject.emtreeVitamin
dc.subject.emtreeCystic fibrosis transmembrane conductance regulator
dc.subject.emtreeAccess to information
dc.subject.emtreeAdolescent
dc.subject.emtreeAge
dc.subject.emtreeAllergic bronchopulmonary aspergillosis
dc.subject.emtreeArticle
dc.subject.emtreeBacterial colonization
dc.subject.emtreeBartter syndrome
dc.subject.emtreeChild
dc.subject.emtreeChild death
dc.subject.emtreeChronic liver disease
dc.subject.emtreeCystic fibrosis
dc.subject.emtreeData analysis software
dc.subject.emtreeDemography
dc.subject.emtreeDiabetes mellitus
dc.subject.emtreeDisease registry
dc.subject.emtreeFemale
dc.subject.emtreeForced expiratory volume
dc.subject.emtreeGastroesophageal reflux
dc.subject.emtreeGastrostomy
dc.subject.emtreeGene frequency
dc.subject.emtreeGene mutation
dc.subject.emtreeGenotype
dc.subject.emtreeHealth care facility
dc.subject.emtreeHemoptysis
dc.subject.emtreeHuman
dc.subject.emtreeInformation processing
dc.subject.emtreeInternet
dc.subject.emtreeLung function
dc.subject.emtreeMajor clinical study
dc.subject.emtreeMale
dc.subject.emtreeMalignant neoplasm
dc.subject.emtreeMeconium ileus
dc.subject.emtreeNewborn screening
dc.subject.emtreeOsteoporosis
dc.subject.emtreePatient care
dc.subject.emtreePneumothorax
dc.subject.emtreePrediction
dc.subject.emtreePreschool child
dc.subject.emtreePriority journal
dc.subject.emtreePseudomonas aeruginosa
dc.subject.emtreePseudomonas infection
dc.subject.emtreeSchool child
dc.subject.emtreeSinusitis
dc.subject.emtreeSweat test
dc.subject.emtreeTurkey (republic)
dc.subject.emtreeCystic fibrosis
dc.subject.emtreeGenetics
dc.subject.emtreeInfant
dc.subject.emtreeMiddle aged
dc.subject.emtreeMutation
dc.subject.emtreeNewborn
dc.subject.emtreeRegister
dc.subject.emtreeTurkey (bird)
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshChild
dc.subject.meshChild, preschool
dc.subject.meshCystic fibrosis
dc.subject.meshCystic fibrosis transmembrane conductance regulator
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInfant
dc.subject.meshInfant, newborn
dc.subject.meshMale
dc.subject.meshMiddle aged
dc.subject.meshMutation
dc.subject.meshNeonatal screening
dc.subject.meshPseudomonas aeruginosa
dc.subject.meshRegistries
dc.subject.meshTurkey
dc.subject.scopusBartter Syndrome; Cystic Fibrosis; Alkalosis
dc.subject.wosPediatrics
dc.subject.wosRespiratory system
dc.titleCystic fibrosis in Turkey: First data from the national registry
dc.typeArticle
dc.wos.quartileQ2 (Pediatrics)
dc.wos.quartileQ3
dc.wos.quartileQ2
dc.wos.quartileQ3
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Dahili Tıp Bilimleri/Çocuk Sağlığı ve Hastalıkları Bölümü
local.indexed.atPubMed
local.indexed.atWOS
local.indexed.atScopus

Dosyalar

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama